RA Capital Management did not report any shares in DYAX and POZN in the third quarter, so these two might be new positions in RA Capital Management’s portfolio. Now RA Capital Management takes 5.29 million shares or 5.36% passive stake in DYAX, and 2.12 million shares or 7.08% passive stake in POZN.
RA Capital Management boosted its stake in SQNM to 5.20%, according to the SEC 13G. As disclosed at the end of September, RA Capital Management had 2.64 million shares in SQNM. So now the firm position is nearly doubled.
Peter Kolchinsky is the co-founder and general partner of RA Capital Management. He graduated from Harvard with a Ph.D. in virology in 2001. After graduation he got $4 Million from Vertex Pharma co-founder Rich Aldrich and started picking biotech stocks at RA Capital. In 2002 he broke even when the S&P 500 index lost 22%. By the end of 2003, the initial $4 Million investment became $13 Million. Boston-based RA Capital invests in companies with promising drugs and technologies.